AIM: To investigate the expression of interferon inducible protein-10 (IP-10) in pancreas of mice and to discuss its possible role in the pathogenesis of type 1 diabetes.METHODS: Non-obese diabetic (NOD) mice were use...AIM: To investigate the expression of interferon inducible protein-10 (IP-10) in pancreas of mice and to discuss its possible role in the pathogenesis of type 1 diabetes.METHODS: Non-obese diabetic (NOD) mice were used as experiment group and BALB/c mice as non-diabetic prone model. Immunohistochemistry method was used to evaluate the expression of IP-10 in the pancreas of NOD mice and BALB/c mice. Immunoelectron microscope was used to show the location of IP-10 in pancreatic islet β cells.RESULTS: Pancreatic islets were positively stained in all the NOD mice. Insulitis could be found in mice at the age of 4 wk. The weakly positive results were found in control group with no insulitis. Immunoelectron microscopy further demonstrated that IP-10 was produced by pancreatic β cells and stored in cytoplasm of the cells.CONCLUSION: IP-10 can be largely produced in pancreatic islets of NOD mice at the age of 2 wk when there is no significant insulitis, and may play an important part in the pathogenesis of type 1 diabetes by attracting immune cells to infiltrate the pancreatic islets.展开更多
目的:评价γ-干扰素诱导蛋白10(IP-10)鉴别结核分枝杆菌不同感染状态的诊断效能.方法:检索Cochrane Library、PubMed、Web of Science、中国知网、维普、万方等数据库,检索自建库至2023年1月的相关文献,进行数据提取和质量评价,采用RevM...目的:评价γ-干扰素诱导蛋白10(IP-10)鉴别结核分枝杆菌不同感染状态的诊断效能.方法:检索Cochrane Library、PubMed、Web of Science、中国知网、维普、万方等数据库,检索自建库至2023年1月的相关文献,进行数据提取和质量评价,采用RevMan 5.3和Stata 17.0软件进行统计分析.结果:共纳入75篇文献,96项研究,共11116例患者.Meta分析结果为IP-10用于鉴别结核感染和非结核感染的合并敏感度为0.82(95%CI:0.79~0.84),特异度为0.87(95%CI:0.84~0.90),阳性似然比为6.40(95%CI:5.20~8.00),阴性似然比为0.21(95%CI:0.18~0.24),诊断比数比为31(95%CI:23~420),受试者工作曲线的曲线下面积为0.91(95%CI:0.88~0.93).结论:IP-10有助于鉴别结核不同感染状态,但最终确诊需要结合病史、症状等进行综合诊断.展开更多
AIM To investigate interferon-γ-inducible protein-10's(IP-10) potential to anticipate rapid(RVR)-and sustained virological responses(SVR) to chronic hepatitis C(CHC) treatment.METHODS We included case series exam...AIM To investigate interferon-γ-inducible protein-10's(IP-10) potential to anticipate rapid(RVR)-and sustained virological responses(SVR) to chronic hepatitis C(CHC) treatment.METHODS We included case series examining RVR or SVR in relation to 24 or 48 wk treatment for CHC,in patients treatment free for at least six months,with genotype 1 or 4,and in relation to 24 wk treatment for genotype 2 and 3,with pegylated interferon in combination with ribavirin.Patients had to have both a baseline IP-10 level as well as a hepatitis C virus(HCV)-RNA determination 4 wk after treatment initiation or 24 wk after end of treatment.Studies including patients with liver diseases other than CHC,human immunodeficiency virus-infection,treatment with immunosuppresents or cytostatica,alcohol dependency or active intravenous drug-use were excluded.We found 81 articles by searching the MEDLINE and EMBASE databases.Eight studies were eligible for inclusion.Their quality were assesed using an 18 point checklist for case series,developed using a modified Delphi technique.Information was extracted from the articles,and no raw data was requisitioned.The review protocol wasregistered at the International Prospective Register of Systematic Reviews(reg.number:CRD42014008736).RESULTS Three studies reported on baseline IP-10 level in association with RVR.A signigficant association was found for HCV genotype 1 infection by two studies.Only two studies reported on HCV genotype 4 infected and genotype 2 and 3 infected patients,respectively.A trend was seen for an association between RVR and baseline IP-10 for genotype 4,while no association was found for genotype 2 and 3.Seven studies provided information regarding baseline IP-10 and SVR.Following the pattern regarding rapid virological response all five studies examining SVR in relation to baseline IP-10 levels for HCV,genotype 1 infected patients showed a significant association.Likewise a significant association was seen for HCV,genotype 4 infected,while no association was found for HCV,genotype 2 and 3 infected.Though only two studies examined the assosiation for HCV genotype 4 infected and HCV genotype 2 and 3 infected respectively.CONCLUSION We found indications of a possible association between baseline IP-10 level and virological responses in patients with CHC genotype 1 and 4.展开更多
Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target ...Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.展开更多
This investigation aimed to unveil new prospective diagnosis-related biomarkers together with treatment targets against glioblastoma.Methods:The expression levels of long non-coding RNA(lncRNA)DPP10-AS1 were assessed ...This investigation aimed to unveil new prospective diagnosis-related biomarkers together with treatment targets against glioblastoma.Methods:The expression levels of long non-coding RNA(lncRNA)DPP10-AS1 were assessed using real-time quantitative polymerase chain reaction(RT-qPCR)within both the patient tissue specimens and glioblastoma cell lines.The relationship between lncRNA DPP10-AS1 expression in glioblastoma and patient prognosis was investigated.Cell Counting Kit-8(CCK-8),transwell,and clonogenic experiments were utilized to assess tumor cells’proliferation,invasiveness,and migratory potentials after lncRNA DPP10-AS1 expression was up or down-regulated.Using an online bioinformatics prediction tool,the intracellular localization of lncRNA DPP10-AS1 and its target miRNA were predicted,and RNA-FISH verified results.A dual-luciferase reporter experiment validated the relationship across miR-24-3p together with lncRNA DPP10-AS1.MiR-24-3p expression within glioblastoma was identified through RT-qPCR,and potential link across miR-24-3p and lncRNA DPP10-AS1 was assessed using Pearson correlation analysis.Moreover,influence from lncRNA DPP10-AS1/miR-24-3p axis upon glioblastoma cell progression was assessed in vivo via a subcutaneous xenograft tumor model.Results:The expression of lncRNA DPP10-AS1 was notably reduced in both surgical specimens of glioblastoma and the equivalent cell lines.Low level of lncRNA DPP10-AS1 in glioblastoma is following poor prognosis.The downregulation of lncRNA DPP10-AS1 in glioblastoma cells resulted in enhanced cellular proliferation,migration,and invasion capabilities,accompanied by downregulated E-cadherin and upregulated vimentin and N-cadherin.Additionally,the observed upregulation of lncRNA DPP10-AS1 demonstrated a substantial inhibitory function upon proliferation,invasion,and migratory capabilities of LN229 cells.Subcellular localization disclosed that lncRNA DPP10-AS1 had a binding site that interacted with miR-24-3p.Upregulated miR-24-3p was detected in glioblastomas,displaying an inverse correlation with lncRNA DPP10-AS1 expression.MiR-24-3p downstream target has been determined as chromodomain helicase DNA binding protein 5(CHD5).LncRNA DPP10-AS1 affected the invasion and proliferation of glioblastoma by controlling the miR-24-3p/CHD5 axis.Conclusion:The present study demonstrated that lncRNA DPP10-AS1 can inhibit the invasive,migratory,and proliferative properties of glioblastoma by regulating the miR-24-3p/CHD5 signaling pathway.Consequently,lncRNA DPP10-AS1 has potential as a tumor suppressor and might be utilized for accurate diagnosis and targeted treatments of glioblastomas.展开更多
文摘AIM: To investigate the expression of interferon inducible protein-10 (IP-10) in pancreas of mice and to discuss its possible role in the pathogenesis of type 1 diabetes.METHODS: Non-obese diabetic (NOD) mice were used as experiment group and BALB/c mice as non-diabetic prone model. Immunohistochemistry method was used to evaluate the expression of IP-10 in the pancreas of NOD mice and BALB/c mice. Immunoelectron microscope was used to show the location of IP-10 in pancreatic islet β cells.RESULTS: Pancreatic islets were positively stained in all the NOD mice. Insulitis could be found in mice at the age of 4 wk. The weakly positive results were found in control group with no insulitis. Immunoelectron microscopy further demonstrated that IP-10 was produced by pancreatic β cells and stored in cytoplasm of the cells.CONCLUSION: IP-10 can be largely produced in pancreatic islets of NOD mice at the age of 2 wk when there is no significant insulitis, and may play an important part in the pathogenesis of type 1 diabetes by attracting immune cells to infiltrate the pancreatic islets.
基金Supported by Amagar and Hvidovre Hospital Research Foun-dation of 45000 Dkr.(to Bastian Neesgaard)The Family Hede Nielsen Foundation of 10000 Dkr.(to Bastian Neesgaard)
文摘AIM To investigate interferon-γ-inducible protein-10's(IP-10) potential to anticipate rapid(RVR)-and sustained virological responses(SVR) to chronic hepatitis C(CHC) treatment.METHODS We included case series examining RVR or SVR in relation to 24 or 48 wk treatment for CHC,in patients treatment free for at least six months,with genotype 1 or 4,and in relation to 24 wk treatment for genotype 2 and 3,with pegylated interferon in combination with ribavirin.Patients had to have both a baseline IP-10 level as well as a hepatitis C virus(HCV)-RNA determination 4 wk after treatment initiation or 24 wk after end of treatment.Studies including patients with liver diseases other than CHC,human immunodeficiency virus-infection,treatment with immunosuppresents or cytostatica,alcohol dependency or active intravenous drug-use were excluded.We found 81 articles by searching the MEDLINE and EMBASE databases.Eight studies were eligible for inclusion.Their quality were assesed using an 18 point checklist for case series,developed using a modified Delphi technique.Information was extracted from the articles,and no raw data was requisitioned.The review protocol wasregistered at the International Prospective Register of Systematic Reviews(reg.number:CRD42014008736).RESULTS Three studies reported on baseline IP-10 level in association with RVR.A signigficant association was found for HCV genotype 1 infection by two studies.Only two studies reported on HCV genotype 4 infected and genotype 2 and 3 infected patients,respectively.A trend was seen for an association between RVR and baseline IP-10 for genotype 4,while no association was found for genotype 2 and 3.Seven studies provided information regarding baseline IP-10 and SVR.Following the pattern regarding rapid virological response all five studies examining SVR in relation to baseline IP-10 levels for HCV,genotype 1 infected patients showed a significant association.Likewise a significant association was seen for HCV,genotype 4 infected,while no association was found for HCV,genotype 2 and 3 infected.Though only two studies examined the assosiation for HCV genotype 4 infected and HCV genotype 2 and 3 infected respectively.CONCLUSION We found indications of a possible association between baseline IP-10 level and virological responses in patients with CHC genotype 1 and 4.
基金supported by Guangdong Basic and Applied Basic Research Foundation(2023A1515010969)Natural Science Foundation of Top Talent of SZTU(GDRC202305).
文摘Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.
基金supported through the Natural Science Foundation of Jiangsu Province(No.BK20201172)the Key Project of the Jiangsu Health Commission(No.ZDB2020016)the Jiangsu Province Key Research and Development Program:Social Development Project(No.BE2021653).
文摘This investigation aimed to unveil new prospective diagnosis-related biomarkers together with treatment targets against glioblastoma.Methods:The expression levels of long non-coding RNA(lncRNA)DPP10-AS1 were assessed using real-time quantitative polymerase chain reaction(RT-qPCR)within both the patient tissue specimens and glioblastoma cell lines.The relationship between lncRNA DPP10-AS1 expression in glioblastoma and patient prognosis was investigated.Cell Counting Kit-8(CCK-8),transwell,and clonogenic experiments were utilized to assess tumor cells’proliferation,invasiveness,and migratory potentials after lncRNA DPP10-AS1 expression was up or down-regulated.Using an online bioinformatics prediction tool,the intracellular localization of lncRNA DPP10-AS1 and its target miRNA were predicted,and RNA-FISH verified results.A dual-luciferase reporter experiment validated the relationship across miR-24-3p together with lncRNA DPP10-AS1.MiR-24-3p expression within glioblastoma was identified through RT-qPCR,and potential link across miR-24-3p and lncRNA DPP10-AS1 was assessed using Pearson correlation analysis.Moreover,influence from lncRNA DPP10-AS1/miR-24-3p axis upon glioblastoma cell progression was assessed in vivo via a subcutaneous xenograft tumor model.Results:The expression of lncRNA DPP10-AS1 was notably reduced in both surgical specimens of glioblastoma and the equivalent cell lines.Low level of lncRNA DPP10-AS1 in glioblastoma is following poor prognosis.The downregulation of lncRNA DPP10-AS1 in glioblastoma cells resulted in enhanced cellular proliferation,migration,and invasion capabilities,accompanied by downregulated E-cadherin and upregulated vimentin and N-cadherin.Additionally,the observed upregulation of lncRNA DPP10-AS1 demonstrated a substantial inhibitory function upon proliferation,invasion,and migratory capabilities of LN229 cells.Subcellular localization disclosed that lncRNA DPP10-AS1 had a binding site that interacted with miR-24-3p.Upregulated miR-24-3p was detected in glioblastomas,displaying an inverse correlation with lncRNA DPP10-AS1 expression.MiR-24-3p downstream target has been determined as chromodomain helicase DNA binding protein 5(CHD5).LncRNA DPP10-AS1 affected the invasion and proliferation of glioblastoma by controlling the miR-24-3p/CHD5 axis.Conclusion:The present study demonstrated that lncRNA DPP10-AS1 can inhibit the invasive,migratory,and proliferative properties of glioblastoma by regulating the miR-24-3p/CHD5 signaling pathway.Consequently,lncRNA DPP10-AS1 has potential as a tumor suppressor and might be utilized for accurate diagnosis and targeted treatments of glioblastomas.
